Clinical research success during the COVID-19 pandemic
The United Kingdom, with its rich history of clinical trials, has long been a preferred destination for conducting cutting-edge research. One of the key factors contributing to its attractiveness is the favourable regulatory environment, particularly when it comes to early development trials. Over the years, the UK has established itself as a frontrunner in clinical research, boasting a remarkable track record of achievements. Notably, it has played a pivotal role in recent successes, such as the rapid development of the COVID-19 vaccines and therapeutic trials.
The COVID-19 pandemic underscored the UK’s prowess in clinical research, showcasing a dynamic collaboration between various stakeholders. This included the government, academic institutions, industry leaders, the National Health Service (NHS), and the public, all united in a shared mission to expedite the development of treatments for an urgent global health crisis.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
